INT-BTX-2150179 | May 2021
In Italy, BOTOX® is indicated and reimbursed by SSN for the management of focal spasticity of the wrist and hand in adult post-stroke patients and focal spasticity of the ankle in adult post-stroke patients.
BOTOX® may not be registered in your country or license terms may vary by country. Please refer to your local prescribing information before prescribing any product.
Materials developed under central/Irish product licence.
Botulinum toxin units are not interchangeable from one product to another; doses recommended in Allergan Units are different from other botulinum toxin preparations. A list of countries with this product/indication is available from UK_Medinfo@Allergan.com.
For Italy only: Classe: H-USPL. Ad uso esclusivo in centri ospedalieri e strutture assimilabili e da specialisti: Neurologo (neuropsichiatra), Neuropsichiatra infantile, Medico specialista in medicina fisica e riabilitativa, Neurofisiopatologo, Oculista, Ortopedico, Urologo, Dermatologo, specialista in Odontoiatria e Odontoiatra. Vietata la vendita al pubblico. Prezzo ex factory (IVA esclusa): € 142,99.
Developed and funded by Allergan, an AbbVie company.
Submitted to AIFA on 24/05/2021